Medicinal composition for joint antiviral therapy and application

Abstract

The invention discloses a medicinal composition for joint antiviral therapy. The medicinal composition is prepared from at least one non-nucleoside reverse transcriptase inhibitor ACC007 serving as an active component and an officinal excipient with a specific quantitative component ratio, and can be also prepared from an active component selected from other non-nucleoside reverse transcriptase inhibitor, a nucleoside (acid) reverse transcriptase inhibitor, a protease inhibitor, an integrase inhibitor, a fusion / entry inhibitor and a compound receptor inhibitor. The invention also discloses application of the medicinal composition to antiviral and anti-HIV (anti-Human Immunodeficiency Virus) therapy. Compared with the prior art, the medicinal composition provided by the invention generates a quite good synergistic effect after being jointly used; a product for treating a virus infection, particularly an HIV infection, is expanded; in addition, the daily dosage of the ACC007 is low, the use level of the excipient can be greatly reduced, the use by a patient is convenient, the medication compliance of the patient is improved, the occurrences of drug-fast phenomena are reduced, and the anti-HIV curative effect is added.

Description

technical field [0001] The invention belongs to the technical field of pharmaceutical preparations, and in particular relates to a pharmaceutical composition with antiviral activity (more specifically, anti-HIV properties). Background technique [0002] Acquired Immunodeficiency Syndrome (Human Acquired Immunodeficiency Syndrome, AIDS), referred to as AIDS, is a systemic infectious disease caused by human immunodeficiency virus (human immunodeficiency virus, HIV). Since the first HIV infection was discovered in the United States in 1981, more than 34 million people have died so far. According to statistics from the World Health Organization (WHO) and the United Nations Program on AIDS (UNAIDS), by the end of 2014, an estimated 36.9 million people worldwide were living with HIV, with an estimated 2 million new infections and 1.2 million deaths in 2014. According to statistics from the Chinese Center for Disease Control and Prevention (CDC), by the end of 2015, there were 577...

AI Technical Summary

Problems solved by technology

But existing above-mentioned preparation also has some defects, for example in Atripla (containing emtricitabine, tenofovir disoproxil fumarate, efavirenz) the consumption of efavirenz is many, and daily consumption has reached 600mg, on the one hand It leads to a large amount of excipients, which is inconvenient for patients to use; on the other hand, it will cause nervous system side effects, and the safe dosage needs to be strictly controlled

Images